Sawai Group Holdings Co., Ltd. (4887.T) Stock

4887.T logo

Sawai Group Holdings Co., Ltd.

4887.TJapan
Healthcare

Company profile

Sawai Group Holdings reported revenue of 189.02 billion JPY for fiscal year 2025, up 6.9% from fiscal year 2024, and net income of 22.94 billion JPY. That is a net profit margin of 12.1% for fiscal year 2025. Our analysis of its filings shows revenue growing from 163.70 billion JPY in fiscal year 2023 to 189.02 billion JPY in fiscal year 2025, 7.5% a year on average. Sawai Group Holdings reports about 3,630 full-time employees.

Figures from company filings; latest fiscal year ended March 31, 2025.

About Sawai Group Holdings Co., Ltd.

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the manufacture and sale of pharmaceuticals. The company offers generic drugs in various dosage forms for therapeutic areas comprising cardiovascular and antibiotic preparations, central nervous system drugs, other metabolic drugs, digestive tract medicines, blood and body fluid medications, allergy medications, respiratory medicine, vitamin supplements, oncology drugs, chemotherapeutic agents, genitourinary and anal drugs, and others. It sells its generic drugs through distributors, wholesalers, and retailers. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

Largest shareholders

  • Nomura Asset Management Co., Ltd.6.45%
  • Silchester International Investors LLP5.81%
  • Sompo Asset Management Co. Ltd.5.13%
  • JPMorgan Asset Management (Japan) Ltd.2.90%
  • Mitsuo Sawai2.744 %2.74%

Share of the company, as of September 25, 2026

Leadership

  • Mitsuo Sawai — Chairman, President, Group CEO & Group COO, 69
  • Taku Nakaoka — Senior MEO, Chief Corp Plan Off, Group CFO and Group Chief Compliance, CSO & Director, 63
  • Hiroki Tada — Group Chief Marketing Officer
  • Ichiro Takahashi — Group Chief Human Resource Officer, Group Chief General Affairs Officer & Chief Branding Officer
  • Toyohiro Sawada — Group Chief Research & Development Officer

How much revenue does Sawai Group Holdings make?

Sawai Group Holdings reported 189.02 billion JPY in revenue for fiscal year 2025, up 6.9% from 176.86 billion JPY in fiscal year 2024.

What companies are similar to Sawai Group Holdings?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ono Pharmaceutical Co., Ltd. (4528.T), Sumitomo Pharma Co., Ltd. (4506.T), Nippon Shinyaku Co., Ltd. (4516.T), Nxera Pharma Co., Ltd. (4565.T).

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees3,630
HeadquartersOsaka, Japan
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
5-2-30, Miyahara, Osaka, 532-0003
Phone
81 6 6105 5818
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Sawai Group Holdings Co., Ltd. (4887.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4887.T

LinkedInLinkedInXXYouTubeYouTube